Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Gray, Ph.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01CA233169 (GRAY, ROBERT J) Sep 18, 2018 - Aug 31, 2023
    Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
    Role: Principal Investigator
  2. U10CA180794 (GRAY, ROBERT J) Apr 29, 2014 - Feb 28, 2025
    ECOG-ACRIN Network Group Statistics and Data Management Center
    Role: Co-Principal Investigator
  3. U10CA066636 (GRAY, ROBERT J) Aug 5, 1994 - Apr 30, 2016
    ECOG Statistical Office Data Management Grant
    Role: Principal Investigator
  4. R01CA057253 (GRAY, ROBERT J) Jul 1, 1992 - Nov 30, 2003
    Role: Principal Investigator
  5. U10CA023318 (GRAY, ROBERT J) Mar 1, 1978 - Apr 30, 2016
    ECOG Statistical Office
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019 Mar 01; 37(7):559-569. PMID: 30650045.
    Citations:    Fields:    
  2. Jayasekera J, Li Y, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA. Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. J Natl Cancer Inst. 2018 Dec 01; 110(12):1360-1369. PMID: 29718314.
    Citations:    Fields:    
  3. Dahlberg SE, Gray RJ. Pragmatic approaches to address expansion cohort design. Cancer. 2018 Aug; 124(16):3290-3292. PMID: 29975413.
    Citations:    Fields:    
  4. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):111-121. PMID: 29860917.
    Citations: 8     Fields:    Translation:Humans
  5. Yeruva SLH, Zhao F, Miller KD, Tevaarwerk AJ, Wagner LI, Gray RJ, Sparano JA, Connolly RM. E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer. 2018; 4:1. PMID: 29354686.
    Citations: 1     
  6. Sparano JA, Gray R, Oktay MH, Entenberg D, Rohan T, Xue X, Donovan M, Peterson M, Shuber A, Hamilton DA, D'Alfonso T, Goldstein LJ, Gertler F, Davidson NE, Condeelis J, Jones J. A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer. 2017; 3:42. PMID: 29138761.
    Citations: 2     
  7. Orbay JL, Gray R, Vernon LL, Sandilands SM, Martin AR, Vignolo SM. The EFCR Approach and the Radial Septum-Understanding the Anatomy and Improving Volar Exposure for Distal Radius Fractures: Imagine What You Could Do With an Extra Inch. Tech Hand Up Extrem Surg. 2016 Dec; 20(4):155-160. PMID: 27801774.
    Citations:    Fields:    Translation:Humans
  8. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Reply to C. Shah et al. J Clin Oncol. 2016 05 20; 34(15):1824-5. PMID: 27001578.
    Citations:    Fields:    
  9. Li S, Gray RJ. Estimating treatment effect in a proportional hazards model in randomized clinical trials with all-or-nothing compliance. Biometrics. 2016 09; 72(3):742-50. PMID: 26799700.
    Citations:    Fields:    Translation:Humans
  10. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19; 373(21):2005-14. PMID: 26412349.
    Citations: 165     Fields:    Translation:Humans
  11. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015 Nov 20; 33(33):3938-44. PMID: 26371148.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  12. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sep 20; 32(27):2959-66. PMID: 25071121.
    Citations: 194     Fields:    Translation:HumansCells
  13. Gray RJ, Zujewski JA, Whelan TJ, Albain KS, Hayes D, Geyer CE, Dees EC, Perez EA, Keane MM, Vallejos Sologuren C, Goggins TF, Mayer IA, Brufsky A, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. J Clin Oncol. 2014 Sep 10; 32(26_suppl):36. PMID: 28141143.
  14. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 09; 111(6):1241-8. PMID: 25117820.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  15. Freidlin B, Korn EL, Gray R. Marker Sequential Test (MaST) design. Clin Trials. 2014 Feb; 11(1):19-27. PMID: 24085774.
    Citations: 7     Fields:    Translation:Humans
  16. Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R. An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology. Clin Trials. 2013 Oct; 10(5):754-60. PMID: 23935162.
    Citations: 1     Fields:    Translation:Humans
  17. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013 May 15; 105(10):701-10. PMID: 23641039.
    Citations: 75     Fields:    Translation:Humans
  18. Freidlin B, Sun Z, Gray R, Korn EL. Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol. 2013 Sep 01; 31(25):3158-61. PMID: 23569306.
    Citations: 6     Fields:    Translation:Humans
  19. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9. PMID: 23340303.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  20. Hong F, Kahl BS, Gray R. Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma. Blood. 2013 Jan 03; 121(1):156-8. PMID: 23160463.
    Citations: 2     Fields:    Translation:HumansCells
  21. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013 Mar 15; 119(6):1140-8. PMID: 23065954.
    Citations: 36     Fields:    Translation:Humans
  22. Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):751-7. PMID: 22706628.
    Citations: 5     Fields:    Translation:HumansCells
  23. Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012 Jul; 134(2):683-92. PMID: 22547108.
    Citations: 12     Fields:    Translation:HumansCells
  24. Kim HT, Gray R. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials. Clin Trials. 2012 Apr; 9(2):155-63. PMID: 22353928.
    Citations: 2     Fields:    Translation:Humans
  25. McGhan LJ, Dueck AC, Gray RJ, Wasif N, McCullough AE, Pockaj BA. The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2012 Sep 01; 106(3):254-9. PMID: 22034211.
    Citations:    Fields:    Translation:Humans
  26. McGhan LJ, Pockaj BA, Gray RJ, Bagaria SP, McLaughlin SA, Casey WJ, Rebecca AM, Wasif N. The impact of breast reconstruction on the decision to undergo contralateral prophylactic mastectomy. J Clin Oncol. 2011 Sep 20; 29(27_suppl):96. PMID: 27957925.
  27. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Gray R. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2011 Nov 15; 17(22):7194-203. PMID: 21933890.
    Citations: 5     Fields:    Translation:Humans
  28. Tewari A, Grover S, Sooriakumaran P, Srivastava A, Rao S, Gupta A, Gray R, Leung R, Paduch DA. Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2012 Feb; 109(4):596-602. PMID: 21851544.
    Citations: 8     Fields:    Translation:Humans
  29. Manola JB, Gray RJ. When bad things happen to good studies. J Clin Oncol. 2011 Sep 10; 29(26):3497-9. PMID: 21844501.
    Citations:    Fields:    Translation:Humans
  30. McKenna P, Robinson AP, Neely D, Desjarlais MP, Carroll DC, Quinn MN, Yuan XH, Brenner CM, Burza M, Coury M, Gallegos P, Gray RJ, Lancaster KL, Li YT, Lin XX, Tresca O, Wahlström CG. Effect of lattice structure on energetic electron transport in solids irradiated by ultraintense laser pulses. Phys Rev Lett. 2011 May 06; 106(18):185004. PMID: 21635098.
    Citations: 1     Fields:    
  31. Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S. An audit strategy for progression-free survival. Biometrics. 2011 Sep; 67(3):1092-9. PMID: 21210772.
    Citations: 4     Fields:    Translation:Humans
  32. Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011 Jan; 6(1):103-8. PMID: 21079521.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  33. Rao RD, Cobleigh MA, Gray R, Graham ML, Norton L, Martino S, Budd GT, Ingle JN, Wood WC. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47. PMID: 20878269.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  34. Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 2010; 12(3):R26. PMID: 20459744.
    Citations: 19     Fields:    Translation:Humans
  35. Wang R, Lagakos SW, Gray RJ. Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring. Biostatistics. 2010 Oct; 11(4):676-92. PMID: 20439258.
    Citations: 6     Fields:    Translation:Humans
  36. Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials. 2010 Jun; 7(3):197-208. PMID: 20423925.
    Citations: 16     Fields:    Translation:Humans
  37. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7693-7700. PMID: 19996222.
    Citations: 12     Fields:    
  38. Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, Lowen MA, Ingle JN, Recht A, Wood WC. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Nov 10; 27(32):5319-24. PMID: 19826126.
    Citations: 59     Fields:    Translation:HumansCTClinical Trials
  39. Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol. 2009 Dec 10; 27(35):5958-64. PMID: 19826121.
    Citations: 8     Fields:    Translation:Humans
  40. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009 Oct 20; 27(30):4966-72. PMID: 19720913.
    Citations: 71     Fields:    Translation:HumansCTClinical Trials
  41. Agarwala SS, Gray RJ, Wong MK. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. J Clin Oncol. 2009 Sep 01; 27(25):e82-3; author reply e84. PMID: 19635995.
    Citations: 2     Fields:    Translation:Humans
  42. DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res. 2009 May 15; 69(10):4184-91. PMID: 19435922.
    Citations: 16     Fields:    Translation:HumansCells
  43. Ruan PK, Gray RJ. Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med. 2008 Nov 29; 27(27):5709-24. PMID: 18712779.
    Citations: 13     Fields:    Translation:Humans
  44. Dahlberg SE, Gray RJ, Johnson BE. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol. 2008 Sep 10; 26(26):4233-5. PMID: 18779608.
    Citations:    Fields:    Translation:Humans
  45. Gray RJ. Weighted analyses for cohort sampling designs. Lifetime Data Anal. 2009 Mar; 15(1):24-40. PMID: 18712477.
    Citations: 21     Fields:    Translation:Humans
  46. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 01; 26(25):4063-71. PMID: 18678838.
    Citations: 85     Fields:    Translation:HumansCTClinical Trials
  47. Goldstein LJ, Gray RJ, Bugarini R, Shak S, Badve SS, Baehner FL, Davidson NE, Sledge GW, Sparano JA. Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197. J Clin Oncol. 2008 May 20; 26(15_suppl):557. PMID: 27948446.
  48. Ruan PK, Gray RJ. Sensitivity analysis of progression-free survival with dependent withdrawal. Stat Med. 2008 Apr 15; 27(8):1180-98. PMID: 17768718.
    Citations: 2     Fields:    Translation:Humans
  49. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008 Mar 01; 14(5):1407-12. PMID: 18316562.
    Citations: 88     Fields:    Translation:HumansCTClinical Trials
  50. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 01; 26(1):60-5. PMID: 18165641.
    Citations: 80     Fields:    Translation:Humans
  51. Freidlin B, Korn EL, George SL, Gray R. Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol. 2007 Nov 01; 25(31):5019-23. PMID: 17971602.
    Citations: 11     Fields:    Translation:Humans
  52. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007 May 20; 25(15):2127-32. PMID: 17513820.
    Citations: 167     Fields:    Translation:Humans
  53. Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol. 2007 May 20; 25(15):2122-6. PMID: 17513819.
    Citations: 22     Fields:    Translation:Humans
  54. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14; 355(24):2542-50. PMID: 17167137.
    Citations: 1551     Fields:    Translation:HumansCTClinical Trials
  55. Gray R. Bayesian modeling approach to examining heterogeneity in censored survival analysis. Biometrics. 2006 Jun; 62(2):623; author reply 623-4. PMID: 16918929.
    Citations: 2     Fields:    Translation:Humans
  56. Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1966-9. PMID: 16609005.
    Citations: 8     Fields:    Translation:Humans
  57. Ruan PK, Gray RJ. A method for analyzing disease-specific mortality with missing cause of death information. Lifetime Data Anal. 2006 Mar; 12(1):35-51. PMID: 16583298.
    Citations: 1     Fields:    Translation:Humans
  58. Lee ML, Gray RJ, Björkbacka H, Freeman MW. Generalized rank tests for replicated microarray data. Stat Appl Genet Mol Biol. 2005; 4:Article3. PMID: 16646848.
    Citations: 2     Fields:    
  59. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Martino S, Tripathy D, Ingle JN, Wood WC. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer. 2004 Sep 01; 101(5):969-72. PMID: 15329905.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  60. Sparano JA, Gray R, Giantonio B, O'Dwyer P, Comis RL. Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res. 2004 Feb 15; 10(4):1206-11. PMID: 14977816.
    Citations: 9     Fields:    Translation:Humans
  61. Keller SM, Vangel MG, Wagner H, Schiller J, Herskovic A, Komaki R, Gray R, Marks RS, Perry MC, Livingston RB, Johnson DH. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer. 2003 Oct; 42(1):79-86. PMID: 14512191.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  62. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26. PMID: 12840088.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  63. Gray RJ. Weighted estimating equations for linear regression analysis of clustered failure time data. Lifetime Data Anal. 2003 Jun; 9(2):123-38. PMID: 12735492.
    Citations: 1     Fields:    Translation:Humans
  64. Gray RJ, Li Y. Optimal weight functions for marginal proportional hazards analysis of clustered failure time data. Lifetime Data Anal. 2002 Mar; 8(1):5-19. PMID: 11878224.
    Citations: 4     Fields:    Translation:Humans
  65. Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001; (30):44-51. PMID: 11773291.
    Citations: 31     Fields:    Translation:Humans
  66. Gray RJ. Estimation of regression parameters and the hazard function in transformed linear survival models. Biometrics. 2000 Jun; 56(2):571-6. PMID: 10877318.
    Citations: 6     Fields:    Translation:Humans
  67. Gray RJ. On tests for group variation with a small to moderate number of groups. Lifetime Data Anal. 1998; 4(2):139-48. PMID: 9658772.
    Citations: 2     Fields:    Translation:Humans
  68. D'Ambra MN, Gray RJ, Hillman R, Jones JW, Kim HC, Rawitscher R, Schnaper H, Szymanski I, Vlahakes GJ, Kaplan D, Lynch KE, Guilfoyle M, Abels RI. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997 Dec; 64(6):1686-93. PMID: 9436556.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  69. Gray RJ. Spline-based tests in survival analysis. Biometrics. 1994 Sep; 50(3):640-52. PMID: 7981391.
    Citations: 22     Fields:    Translation:Humans
  70. Gray RJ. A Bayesian analysis of institutional effects in a multicenter cancer clinical trial. Biometrics. 1994 Mar; 50(1):244-53. PMID: 8086608.
    Citations: 17     Fields:    Translation:Humans
  71. Gray RJ. Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics. 1990 Mar; 46(1):93-102. PMID: 2190638.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  72. Gray RJ, Tsiatis AA. A linear rank test for use when the main interest is in differences in cure rates. Biometrics. 1989 Sep; 45(3):899-904. PMID: 2790128.
    Citations: 25     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Gray's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (207)
Co-Authors (15)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.